FDA clears Ventana's image analysis app for cancer detection

Ventana Medical Systems has been granted 510(k) clearance to go to market with an image analysis application used to detect breast and other types of cancer. The Ventana Companion HER2 (4B5) application assists pathologists with interpretation of images of a certain protein in tissue, according to a company statement.

Also receiving clearance was a Ventana application that allows digital reading of slides stained with the same protein. Both applications work with the company’s Virtuoso software and iScan Coreo Au scanner.

Oro Valley, Ariz.-based Ventana is owned by the Swiss pharmaceutical firm Roche.

 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.